GlassScriptPhysician profile
Kayla Lanette Mack
NPI 1295329274
$862.86
in general payments reported to CMS, 2019-2025
15 companies · $519 in 2025
The $519 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $63.03 · 2023: $88.77 · 2024: $192 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $732 · Education: $67.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $731.88 |
| Education | $67.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $199.69 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Beta Bionics, INC. | $160.52 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Astellas Pharma US INC | $88.21 | 2025 | Veozah |
| Corium, LLC | $67.82 | 2024 | Azstarys |
| Amgen INC. | $60.93 | 2023-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $59.93 | 2023-2025 | |
| Lilly USA, LLC | $48.03 | 2022-2025 | Mounjaro, Zepbound |
| Verona Pharma, INC. | $44.90 | 2025 | Ohtuvayre |
| Shield Therapeutics INC | $29.87 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.02 | 2025 | Iclusig |
| Sanofi-Aventis U.S. LLC | $18.55 | 2025 | |
| Janssen Pharmaceuticals, INC | $17.38 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $15.24 | 2024 | |
| Phadia US INC. | $15.05 | 2022 | |
| Esperion Therapeutics, INC. | $12.72 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Mack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.